0001104659-17-035028.txt : 20170525 0001104659-17-035028.hdr.sgml : 20170525 20170525091915 ACCESSION NUMBER: 0001104659-17-035028 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20170525 FILED AS OF DATE: 20170525 DATE AS OF CHANGE: 20170525 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Strongbridge Biopharma plc CENTRAL INDEX KEY: 0001634432 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981130690 STATE OF INCORPORATION: L2 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37569 FILM NUMBER: 17868434 BUSINESS ADDRESS: STREET 1: 900 NORTHBROOK DRIVE, SUITE 200 CITY: TREVOSE STATE: PA ZIP: 19053 BUSINESS PHONE: (610) 254-9200 MAIL ADDRESS: STREET 1: 900 NORTHBROOK DRIVE, SUITE 200 CITY: TREVOSE STATE: PA ZIP: 19053 FORMER COMPANY: FORMER CONFORMED NAME: Cortendo AB DATE OF NAME CHANGE: 20150219 6-K 1 a17-14166_16k.htm 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934

 

For the month of May 2017

 

Commission File Number:  001-37569

 

STRONGBRIDGE BIOPHARMA plc

(Exact name of Registrant as specified in its charter)

 

900 Northbrook Drive

Suite 200

Trevose, PA 19053

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x   Form 40-F o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

 

 

 


 

On May 25, 2017, Strongbridge Biopharma plc (the “Registrant”) issued a press release announcing that Matthew Pauls, president and chief executive officer, is scheduled to present at the Jefferies 2017 Global Healthcare Conference, taking place June 6-9, 2017, in New York City.

 

The presentation will be webcast live and available on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com

 

The information contained in the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any of the Registrant’s registration statements or other filings with the Commission.

 

Exhibits

 

Exhibit
Number

 

Exhibit Table

 

 

 

99.1

 

Press Release issued by Strongbridge Biopharma plc, dated May 25, 2017.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

Dated: May 25, 2017

STRONGBRIDGE BIOPHARMA PLC

 

 

 

 

 

By:

/s/ Stephen Long

 

 

Stephen Long

 

 

Chief Legal Officer

 

3

 EX-99.1 2 a17-14166_1ex99d1.htm EX-99.1

Exhibit 99.1

 

 

Strongbridge Biopharma plc to Present at the Jefferies 2017 Global Healthcare Conference

 

DUBLIN, Ireland and TREVOSE, Pa., May 25, 2017 — Strongbridge Biopharma plc (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will present at the Jefferies 2017 Global Healthcare Conference, taking place June 6-9 at the Grand Hyatt in New York City.

 

Matthew Pauls, president and chief executive officer of Strongbridge Biopharma, will provide a corporate overview on Friday, June 9 at 10:30 a.m. ET. The presentation will be webcast live and archived on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.

 

About Strongbridge Biopharma

 

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S. through August 7, 2022. In addition to establishing this neuromuscular disease franchise, the Company has a clinical-stage pipeline of therapies for rare endocrine diseases. Strongbridge’s lead compounds include RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing’s syndrome, and veldoreotide, a next-generation somatostatin analog being investigated for the treatment of acromegaly, with potential additional applications in Cushing’s syndrome and neuroendocrine tumors. Both RECORLEV and veldoreotide have received orphan designation from the U.S. Food and Drug Administration and the European Medicines Agency. For more information, visit www.strongbridgebio.com.

 

Contacts:

 

Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco

 


 

+1 862-596-1304
lrocco@elixirhealthpr.com

 

Investor Relations
The Trout Group
Marcy Nanus
+1 646-378-2927
mnanus@troutgroup.com

 

USA
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. +1 610-254-9200
Fax. +1 215-355-7389

 

 GRAPHIC 3 g141661mmi001.jpg GRAPHIC begin 644 g141661mmi001.jpg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

FT5U^T?+RB///#GA;5[#XHZKJ]U:;+"?SO+E\ MQ#NW,". E4M6\ WFN?%2:^U"P,FAS ;Y!.J]( HX#;OO@=OTKU"BCVLK MW\K >4^%_ FK:'K.J:;>:>MSHU_$UN;Q7C#JO.U@"=PZ\C'7!YQ56PT'Q[X( MDNK/0XH[RSE8LKC:5STW!205;&,]N.^*]@HI^V;W0'C\/PTUK_A&=:N[U1<: MYJ 0)")%X'FJ[EF)VY.WU[>^*OR_#6YU'X;Z?:SP+!KEB)2@+J=P,C-L+ XY M!!'/!^IKU&BCVT@/&K'X6:M=^#IK:\B6TU*&Z::W5Y%974HH8$J3C)4?E[YJ M'4_#WCKQ!:PV&HZ-:.\06,7KB+S=JYP#)NSCGMUKVNO+9;W4XH+S4(Y]:!AO MW7S_ +1NMHT$F#F/DD >U7&I*3-(0YC+O? GBC3-:TZYTS3[>^^QVJ1[GDC\ MMF ((VLP)'- \"^*]:UU]2U+3[2P*0MA8&C42$*0% 5CR20"2>E=7K&M7MK> M:^MM=NBMX\-ZOI!M]5O;M+RX%O-!=3&3<" M"=Z^F.^/44_:2#V9P^G?":]G\)7WVZS^SZTDN^V)F5A(@4?*<,5&3GD\YQVJ M?4/"GBC4? %AH[Z*D=S8W65V30@21E6^8X;&03@^O!YYK4TZ[OYG@DLKS6I] M0-\RLC%WM1&)"#G/&-OH:F'B+48O#^O1BWU*9EN+A4O%?*PCL,DY&/:FY3N5 M[%]S!N_"7C&P\70ZQH^FHTD-O"B,\T6-PMUC<8+>NX5J:%X"US6/$ZZYXS=- MT>"L 926(^Z/EX"CKP:T?%FORQV^FV%MJ?V.X%M]KEE+D%B%^1">^YNN:EUG M6_[6A\.7,,^HQ6]X)3,FGLWF$A.@"\G# _AFIYI-(2I/0YC_ (0[Q9X/O;V# M0[6WU32[OAHY@CJP'0.C$.0X MYVJH"' S6_\ ;M3N/#-U)8:A?"VEU"**QGN)?WN"<-N(YQGUJVFM:YJ.N:/) ME:?)K?]G6WVJUACG\I?,1"N%; R!@] :Y6_\ &'E>,3=# M40MC;7"V;6N\X=2#OEQTX8C!]!7HE95)-VNB)P<;7%HHHK(@**** "BBB@ H MHHH **** "BBB@ KGV\$:+)/)))!*XDD,CQM.^QF)R6/1=Q.** M*=V',[;E[3]/M],MOL]JA6/>SX))Y8Y/7W-5TT&QCT^[L5B;[/=N[S+O/)?[ MW/:BBE=A=W);+2;33[B>>W0B6<(KLS$Y"#"CGH *@M_#FG6MU%/#$RO#-)/& M-YPK2##8'H1VZ"BBB["[&_\ "-:;F;$+*LUPMTR*Y"^8IR& [>_K5N]TZWOW MMWN%8M;R>9&0Q&UL$9_(T44[L+LBCT.PBT5M)6'_ $-E92A8DD$DGGKG)SFK 9EO"EM;Q01YV1H$7)R< 8'/>BBDV)ML__V0$! end